Active Ingredient History
Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Tissue Adhesions (approved 2012)
Arterial Occlusive Diseases (Phase 2)
Diabetic Retinopathy (Phase 3)
Disease Progression (Phase 2)
Eye Diseases (Phase 2)
Macular Degeneration (Phase 2)
Macular Edema (Phase 2)
Retinal Vein Occlusion (Phase 1)
Stroke (Phase 2)
Tissue Adhesions (Phase 4)
Uveitis (Phase 1/Phase 2)
Venous Thrombosis (Phase 2)
Vitrectomy (Phase 2)
Vitreous Body (Phase 4)
Vitreous Detachment (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
